In this respect, it was a crucial finding that cleavage of the JAM-A extracellular domain (which would be increasingly likely in JAM-overexpressing settings) is associated with resistance to HER2-targeted therapies and that cleaved JAM-A promotes the invasive potential of breast cancer cells in vitro and in a semi-in vivo model. This evidence concerns the gene F11R and breast cancer.